3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Waldenstrom Macroglobulinemia
1
Recurrence
1
Paraproteinemias
1
Neoplasms, Plasma Cell
1
Neoplasms
1
Multiple Myeloma
1
Lymphoproliferative Disorders
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Immunoproliferative Disorders
1
Hematologic Diseases
1
Blood Protein Disorders
1
Interventions
fludarabine phosphate
4
fludarabine
4
Cyclophosphamide
4
blinatumomab
3
ponatinib
2
ibrutinib
2
Whole-Body Irradiation
2
Tacrolimus
2
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
Mycophenolic Acid
2
Mesna
2
Melphalan
2
Busulfan
2
Bone Marrow Transplantation
2
AP 1903 reagent
2
pegaspargase
1
durvalumab
1
asparaginase erwinia chrysanthemi recombinant
1
Rituximab
1
Pharmacogenomic Testing
1
Methotrexate
1
Lenalidomide
1
KW-2478
1
Imatinib Mesylate
1
Ifosfamide
1
Hsp90 inhibitor KU757
1
Dexamethasone
1
Daunorubicin
1
CLR1404
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Immunoproliferative Disorders
×
CLR1404
×
Other hematologic neoplasm
×
Clear all
NCT02952508
2026-03-18
CLOVER-WaM
Cellectar Biosciences, Inc.
Phase 2
Active not recruiting
120 enrolled